ACADIA Pharmaceuticals to Present at the 2005 UBS Global Life Sciences Conference on September 27, 2005
SAN DIEGO, Sept. 20 /PRNewswire-FirstCall/ — ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) announced today that Uli Hacksell, Ph.D., Chief Executive Officer, will present at the 2005 UBS Global Life Sciences Conference on Tuesday, September 27, 2005, at 10:00 a.m. Eastern Time at the Grand Hyatt New York in New York City.
A live webcast of ACADIA’s presentation will be accessible on the company’s website, www.acadia-pharm.com, under the investors section and an archived recording will be available on the website through October 11, 2005.
About ACADIA Pharmaceuticals
ACADIA Pharmaceuticals is a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders. ACADIA currently has four drug programs in clinical development as well as a portfolio of preclinical and discovery assets directed at large unmet medical needs, including schizophrenia, Parkinson’s disease, neuropathic pain, and glaucoma. Using its proprietary drug discovery platform, ACADIA has discovered all of the drug candidates in its product pipeline. ACADIA’s corporate headquarters is located in San Diego, California, and it maintains research and development operations in both San Diego and Malmo, Sweden.
Lisa Barthelemy, Director, Investor Relations, or Thomas H. Aasen, Vice President and Chief Financial Officer, both of ACADIA Pharmaceuticals Inc., +1-858-558-2871
Web site: http://www.acadia-pharm.com (ACAD)